文献速递胸部肿瘤

舒格利单抗对比安慰剂联合铂类化疗一线治疗转移性非小细胞肺癌(GEMSTONE-302):双盲随机3期临床试验的中期与最终分析

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
PubMed 文献 · Lancet Oncol · 2022-01-14

GEMSTONE-302研究在中国35家医院开展,479例IV期鳞状或非鳞状非小细胞肺癌患者按2:1随机接受舒格利单抗或安慰剂联合铂类化疗。中期分析(随访8.6个月)中位无进展生存期舒格利单抗组7.8个月 vs 安慰剂组4.9个月(分层HR 0.50,95%CI 0.39-0.64,p<0.0001);最终分析(随访17.8个月)中位无进展生存期9.0个月 vs 4.9个月(分层HR 0.48,95%CI 0.39-0.60,p<0.0001)。

要点

  • 舒格利单抗联合化疗较安慰剂联合化疗显著延长中位无进展生存期(最终分析9.0个月 vs 4.9个月,分层HR 0.48)。
  • 鳞状和非鳞状转移性NSCLC患者均可从舒格利单抗联合化疗中获益, regardless of PD-L1表达。
  • 两组≥3级治疗相关不良事件发生率相似,最常见为中性粒细胞计数降低(33% vs 33%)。

核心结论

  • 舒格利单抗联合化疗较安慰剂联合化疗在既往未治疗的鳞状和非鳞状转移性NSCLC患者中显示出统计学显著且具有临床意义的无进展生存期改善, regardless of PD-L1表达。
  • 舒格利单抗联合化疗可能成为鳞状和非鳞状转移性NSCLC的新一线治疗选择。

研究设计与样本

  • 随机、双盲、3期临床试验,在中国35家医院和学术研究中心开展。
  • 纳入年龄18-75岁、组织学或细胞学确诊的IV期鳞状或非鳞状NSCLC患者,无已知EGFR致敏突变、ALK、ROS1或RET融合,未接受过转移性疾病全身治疗,ECOG体能状态评分0或1。
  • 患者按2:1随机分配至舒格利单抗组(n=320)或安慰剂组(n=159),随机分层因素为ECOG体能状态、PD-L1表达和肿瘤病理。
  • 主要终点为意向治疗人群的研究者评估无进展生存期;安全性分析纳入至少接受一剂治疗的所有患者。

主要发现

  • 中期分析(数据截止2020年6月8日;中位随访8.6个月[IQR 6.1-11.4])中位无进展生存期舒格利单抗组7.8个月(95%CI 6.9-9.0) vs 安慰剂组4.9个月(95%CI 4.7-5.0),分层HR 0.50(95%CI 0.39-0.64),p<0.0001。
  • 最终分析(2021年3月15日;中位随访17.8个月[IQR 15.1-20.9])中位无进展生存期舒格利单抗组9.0个月(95%CI 7.4-10.8) vs 安慰剂组4.9个月(95%CI 4.8-5.1),分层HR 0.48(95%CI 0.39-0.60),p<0.0001。
  • 最常见的≥3级任何治疗相关不良事件:中性粒细胞计数降低(舒格利单抗组104/320[33%] vs 安慰剂组52/159[33%])、白细胞计数降低(45[14%] vs 27[17%])、贫血(43[13%] vs 18[11%])、血小板计数降低(33[10%] vs 15[9%])、中性粒细胞减少(12[4%] vs 7[4%])。
  • 任何治疗相关严重不良事件:舒格利单抗组73例(23%) vs 安慰剂组31例(20%)。
  • 任何治疗相关死亡:舒格利单抗组10例(3%) vs 安慰剂组2例(1%)。

关键数值与推荐

  • 舒格利单抗1200 mg静脉注射每3周一次,联合铂类化疗(鳞状NSCLC:卡铂AUC 5 mg/mL per min静脉注射+紫杉醇175 mg/m2静脉注射;非鳞状NSCLC:卡铂AUC 5 mg/mL per min静脉注射+培美曲塞500 mg/m2静脉注射),最多4个周期。
  • 维持治疗:鳞状NSCLC予舒格利单抗或安慰剂;非鳞状NSCLC予舒格利单抗500 mg/m2静脉注射或匹配安慰剂+培美曲塞。

临床怎么用

  • 舒格利单抗联合铂类化疗可作为既往未治疗的鳞状和非鳞状转移性NSCLC患者的新一线治疗选择, regardless of PD-L1表达(作者结论)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there was no robust evidence showing a PD-L1 inhibitor combined with chemotherapy benefited patients with squamous and non-squamous NSCLC. GEMSTONE-302 aimed to evaluate the efficacy and safety of a PD-L1 inhibitor, sugemalimab, plus chemotherapy for patients with metastatic squamous or non-squamous NSCLC. METHODS: This randomised, double-blind, phase 3 trial was done in 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years, had histologically or cytologically confirmed stage IV squamous or non-squamous NSCLC without known EGFR sensitising mutations, ALK, ROS1, or RET fusions, no previous systemic treatment for metastatic disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned (2:1) to receive sugemalimab (1200 mg, intravenously, every 3 weeks) plus platinum-based chemotherapy (carboplatin [area under the curve (AUC) 5 mg/mL per min, intravenously] and paclitaxel [175 mg/m2, intravenously] for squamous NSCLC, or carboplatin [AUC 5 mg/mL per min, intravenously] and pemetrexed [500 mg/m2, intravenously] for non-squamous NSCLC; sugemalimab group) or placebo plus the same platinum-based chemotherapy regimens for squamous or non-squamous NSCLC as in the sugemalimab group; placebo group) for up to four cycles, followed by maintenance therapy with sugemalimab or placebo for squamous NSCLC, and intravenous sugemalimab 500 mg/m2 or matching placebo plus pemetrexed for non-squamous NSCLC. Randomisation was done by an interactive voice-web-response system via permuted blocks (block size was a mixture of three and six with a random order within each stratum) and stratified by ECOG performance status, PD-L1 expression, and tumour pathology. The investigators, patients, and the sponsor were masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one treatment dose. Results reported are from a prespecified interim analysis (ie, when the study met the primary endpoint) and an updated analysis (prespecified final analysis for progression-free survival) with a longer follow-up. This study is registered with ClinicalTrials.gov (NCT03789604), is closed to new participants, and follow-up is ongoing. FINDINGS: Between Dec 13, 2018, and May 15, 2020, 846 patients were assessed for eligibility; 367 were ineligible, and the remaining 479 patients were randomly assigned to the sugemalimab group (n=320) or placebo group (n=159). At the preplanned interim analysis (data cutoff June 8, 2020; median follow-up 8·6 months [IQR 6·1-11·4]), GEMSTONE-302 met its primary endpoint, with significantly longer progression-free survival in the sugemalimab group compared with the placebo group (median 7·8 months [95% CI 6·9-9·0] vs 4·9 months [4·7-5·0]; stratified hazard ratio [HR] 0·50 [95% CI 0·39-0·64], p<0·0001]). At the final analysis (March 15, 2021) with a median follow-up of 17·8 months (IQR 15·1-20·9), the improvement in progression-free survival was maintained (median 9·0 months [95% CI 7·4-10·8] vs 4·9 months [4·8-5·1]; stratified HR 0·48 [95% CI 0·39-0·60], p<0·0001). The most common grade 3 or 4 any treatment-related adverse events were neutrophil count decreased (104 [33%] of 320 with sugemalimab vs 52 [33%] of 159 with placebo), white blood cell count decreased (45 [14%] vs 27 [17%]), anaemia (43 [13%] vs 18 [11%]), platelet count decreased (33 [10%] vs 15 [9%]), and neutropenia (12 [4%] vs seven [4%]). Any treatment-related serious adverse events occurred in 73 (23%) patients in the sugemalimab group and 31 (20%) patients in the placebo group. Any treatment-related deaths were reported in ten (3%) patients in the sugemalimab group (pneumonia with respiratory failure in one patient; myelosuppression with septic shock in one patient; pneumonia in two patients; respiratory failure, abdominal pain, cardiac failure, and immune-mediated pneumonitis in one patient each; the other two deaths had an unspecified cause) and in two (1%) patients in the placebo group (pneumonia and multiple organ dysfunction syndrome). INTERPRETATION: Sugemalimab plus chemotherapy showed a statistically significant and clinically meaningful progression-free survival improvement compared with placebo plus chemotherapy, in patients with previously untreated squamous and non-squamous metastatic NSCLC, regardless of PD-L1 expression, and could be a newfirst-line treatment option for both squamous and non-squamous metastatic NSCLC. FUNDING: CStone Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022. PMID: 35038432. doi:10.1016/S1470-2045(21)00650-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。